Skip to main content

Table 2 Correlation of preoperative CTC number to clinicopathological characteristics

From: A prospective study on the changes and clinical significance of pre-operative and post-operative circulating tumor cells in resectable gastric cancer

Characteristics

3-year recurrence rate%

No. of patients (%)

CTC ≥ 1/7.5 ml

CTC ≥ 2/7.5 ml

CTC ≥ 3/7.5 ml

CTC ≥ 4/7.5 ml

CTC ≥ 5/7.5 ml

Gender

 Male (n = 68)

65.6

23 (33.8%)

9 (13.2%)

6 (8.8%)

5 (7.4%)

5 (7.4%)

 Female (n = 25)

63.1

8 (32.0%)

4 (16.0%)

3 (12.0%)

1 (4.0%)

0 (0.0%)

 p value

0.658

0.869

0.997

0.949

1.000

0.319

Age

 ≤ 45 (n = 16)

58.3

6 (37.5%)

4 (25.0%)

4 (25.0%)

2 (12.5%)

1 (6.3%)

 > 45 (n = 77)

66.2

25 (32.5%)

9 (11.7%)

5 (6.5%)

4 (5.2%)

4 (5.2%)

 p value

0.244

0.698

0.317

0.070

0.274

1.000

Primary sitea

 EGJ (n = 29)

50.4

9 (31.0%)

3 (10.3%)

2 (6.9%)

2 (6.9%)

2 (6.9%)

 Non-EGJ (n = 64)

71.2

22 (34.3%)

10 (15.6%)

7 (10.9%)

4 (6.3%)

3 (4.7%)

 p value

0.002

0.873

0.787

0.873

1.000

0.635

Differentiationb

 Good (n = 22)

71.8

4 (18.2%)

1 (4.5%)

1 (4.5%)

0 (0.0%)

0 (0.0%)

 Poor (n = 71)

62.6

27 (38.0%)

12 (16.9%)

8 (11.3%)

6 (8.5%)

5 (7.0%)

 p value

0.174

0.084

0.268

0.604

0.330

0.335

Lauren

 Intestinal (n = 36)

68.0

8 (22.2%)

2 (5.6%)

1 (2.8%)

0 (0.0%)

0 (0.0%)

 Diffuse (n = 23)

67.4

6 (26.1%)

5 (21.7%)

5 (21.7%)

3 (13.0%)

2 (8.7%)

 Mixed (n = 34)

60.0

17 (50.0%)

6 (17.6%)

3 (8.8%)

3 (8.8%)

3 (8.8%)

 p value

0.434

0.033

0.118

0.060

0.068

0.148

TNM classification

 I (n = 24)

100.0

6 (25.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

 II (n = 24)

68.3

8 (33.3%)

4 (16.7%)

2 (8.3%)

1 (4.2%)

1 (4.2%)

 III (n = 45)

44.0

17 (37.8%)

9 (20.0%)

7 (15.6%)

5 (11.1%)

4 (8.9%)

 p value

0.000

0.563

0.047

0.103

0.306

0.443

Depth of penetration

 T1/T2 (n = 30)

90.0

8 (26.7%)

1 (3.3%)

1 (3.3%)

1 (3.3%)

1 (3.3%)

 T3 (n = 34)

56.9

12 (35.3%)

5 (14.7%)

1 (2.9%)

0 (0.0%)

0 (0.0%)

 T4 (n = 29)

47.7

11 (37.9%)

7 (24.1%)

7 (24.1%)

5 (17.2%)

4 (13.8%)

 p value

0.000

0.627

0.064

0.007

0.009

0.026

Lymph node

 N0 (n = 31)

96.8

7 (22.6%)

2 (6.5%)

1 (3.2%)

0 (0.0%)

0 (0.0%)

 N1/N2 (n = 31)

58.4

9 (29.0%)

3 (9.7%)

2 (6.5%)

2 (6.5%)

2 (6.5%)

 N3 (n = 31)

38.9

15 (48.4%)

8 (25.8%)

6 (19.4%)

4 (12.9%)

3 (9.7%)

 p value

0.000

0.081

0.109

0.133

0.160

0.362

Lymph-vascular invasion

 Yes (n = 45)

53.0

20 (44.4%)

9 (20.0%)

6 (13.3%)

3 (6.7%)

3 (6.7%)

 No (n = 48)

75.8

11 (22.9%)

4 (8.3%)

3 (6.3%)

3 (6.3%)

2 (4.2%)

 p value

0.001

0.028

0.105

0.307

1.000

0.671

CEAc level before operation (ng/ml)

 < 5 (n = 75)

68.8

26 (34.7%)

12 (16.0%)

9 (12.0%)

6 (8.0%)

5 (6.7%)

 ≥ 5 (n = 17)

46.3

5 (29.4%)

1 (5.9%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

 NAd (n = 1)

 

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

 P value

0.001

0.679

0.487

0.293

0.589

0.580

  1. Italic values indicate that there are significant differences in pre-operative CTCs between different clinicopathological types
  2. aEGJ, gastroesophageal junction
  3. bGood, including high or moderate differentiation; Poor, including low differentiation, mucinous adenocarcinoma, and signet-ring cell carcinoma
  4. ccarcinoembryonic antigen
  5. dnon-available